Fig. 1



0.3
0.2
0.1
0.0
NE Activity (mU/mL eq)
****
****
****
vehicle/ fMLP
Drug (0.3 mg/kg)/ fMLP
Drug (3 mg/kg)/ fMLP
Drug (30 mg/kg)/ fMLP
Inhalation dosing

Fig. 2



0.4
0.3
0.2
0.1
0.0
NE Activity (mU/mL eq)
vehicle/ fMLP
Drug (0.3 mg/kg)/ fMLP
Drug (3 mg/kg)/ fMLP
Drug (30 mg/kg)/ fMLP
Inhalation dosing

Fig. 3



Active compound in plasma [µM]
0.6
0.4
0.2
0.0
0
5
10
15
20
Time [h]
Cohort 1 (80 mg)
Cohort 2 (160 mg)
Cohort 3 (320 mg)

Fig. 4




Active compound in sputum [µM]
1000
100
10
0-1
1-3
24
Time [h]
Cohort 1 (80 mg)
Cohort 2 (160 mg)
Cohort 3 (320 mg)

Fig. 5


3.00
2.50
2.00
1.50
1.00
0.50
0.00
Active elastase, means [µM]
predose
1-3
24
Time [h]
mean 80 mg
mean 160 mg
mean 320 mg
mean placebo